Evidence map›Paper›PMID 42046069›Full record

ArticleJournal of cheminformatics2026

LEP-AD: language embedding of proteins and attention to drugs predicts drug-target interactions.

Reem Alsulami, Robert Lehmann, Anuj Daga, Sumeer A Khan, Raik Grünberg, Ahmed Abogosh, David Gomez Cabrero, Stefan T Arold, Robert Hoehndorf, Jesper Tegner and 1 more

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Reem AlsulamiComputer, Electrical and Mathematical Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia.
Robert Lehmann *Division of Biomedical Sciences, King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia. robert.lehman@kaust.edu.sa.
Anuj DagaComputer, Electrical and Mathematical Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia.
Sumeer A KhanDivision of Biomedical Sciences, King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia.
Raik GrünbergDivision of Biomedical Sciences, King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia.
Ahmed AbogoshDivision of Biomedical Sciences, King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia.
David Gomez CabreroDivision of Biomedical Sciences, King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia.
Stefan T AroldComputer, Electrical and Mathematical Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia.
Robert HoehndorfDivision of Biomedical Sciences, King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia.
Jesper Tegner *Computer, Electrical and Mathematical Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia. jesper.tegner@kaust.edu.sa.
Narsis A Kiani *Algorithmic Dynamic Lab, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden. narsis.kiani@ki.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPredicting drug-target interactions remains a significant challenge in drug development and lead optimization. Recent advances have leveraged machine learning algorithms to model drug-target interactions from molecular and sequence data. MATERIALS AND

methodsIn this work, we use Evolutionary Scale Modeling (ESM-3) to construct a transformer-based protein language representation for drug-target interaction prediction. We introduce LEP-AD (Language Embedding of Proteins and Attention to Drugs), a modular architecture that combines pretrained protein language models with graph-based molecular encoders to predict binding affinity values.

resultsWe systematically benchmark LEP-AD alongside a range of established deep learning methods across multiple datasets-Davis, KIBA, DTC, Metz, ToxCast, and STITCH. To assess predictive validity, we compare model-derived rankings of drug-target interactions with experimental results reported in the literature. In addition, we perform new experimental assays to evaluate the binding of three ATP-competitive Src kinase inhibitors-Dasatinib, UM-164, and Saracatinib-where experimentally measured IC₅₀ and pKᵢ values are consistent with the predicted rankings.

conclusionIn summary, our benchmark highlights the strengths and limitations of current drug-target interaction models across diverse datasets and evaluation settings. The results emphasize the impact of pretrained protein and molecular representations on predictive performance and illustrate the persistent challenges of generalization, while the modular LEP-AD framework provides a flexible reference point for comparative evaluation. SCIENTIFIC CONTRIBUTION: This study presents LEP-AD, a modular deep learning framework for drug-target interaction prediction that integrates pretrained protein language representations with graph-based molecular encoders. Beyond introducing the architecture, we provide a systematic benchmark under similarity-aware evaluation settings and experimental validation, highlighting the impact of pretrained protein embeddings on predictive behavior across diverse datasets.

Indexed as

Binding affinityDrug discoveryDrug target affinityDTIESMGATGCN

Identifiers

PMID42046069
PMCPMC13397736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.